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Net Thromboembolic vs. Bleeding Risk Stratification: A Step Forward for 
Personalized and Tailored Treatment of Atrial Fibrillation. 
 
 
Words: 254 (<250) 
 
Hijazi and colleagues’ ABC score yields promise as a new standard for 
assessming bleeding risk in patients with atrial fibrillation (AF) and supports the 
role of biomarkers in the field [1]. Unfortunately, it also highlights the overlap of 
some variables (GDF-15, Troponin T, and age) which not only associate with 
bleeding, but are also known risk factors for stroke and systemic embolism [2, 3]. 
New thromboembolic risk stratification schemes like ATRIA [4], R2CHADS2 [5] 
and ABC-stroke [6] have been proposed, but it is clear the time has come for a 
new paradigm of integrated  risk stratification for AF patients. Using two 
separate risk classifications to assess the two ends of a continuous spectrum 
(thrombosis vs. bleeding) seems artificial and provides unclear guidance in the 
frequent setting of increased bleeding and thrombotic risk. We propose that a 
combined risk score assessing thromboembolic risk and simultaneously 
adjusting/balancing for bleeding risk, providing us with a net risk/benefit 
estimation may be the way to achieve a personalized treatment in this 
population. This could potentially allow tailoring of anticoagulation according to 
each patient’s net risk, possibly allowing higher intensity anticoagulation 
regimens for patients with high thromboembolic risk but low bleeding risk, and 
lower intensity anticoagulation in those with low to moderate thromboembolic 
risk and higher bleeding tendency. Integrating and merging the different risk 
assessment tools (bleeding and thromboembolic risk scores), including variables 
signalling only higher thromboembolic risk or adjusting for thrombotic risk 
factors to the bleeding tendency may be the way forward. In the future 
strucutural information when they are validated (eg. Left atrial appendage 
morphology/velocities), as well as biomarkers could also be incorporated to 
refine the scoring system.  
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